Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bristol-Myers Squibb Company, in collaboration with K36 Therapeutics, is conducting a Phase 1 study titled A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma. The study aims to evaluate the safety and preliminary efficacy of KTX-1001, a novel inhibitor targeting the MMSET enzyme, in patients with relapsed or refractory multiple myeloma (RRMM).
The intervention involves KTX-1001, an oral drug designed to inhibit MMSET, potentially improving outcomes for RRMM patients. It is tested alone and in combination with other therapies like Mezigdomide, carfilzomib, and pomalidomide.
This open-label, non-randomized study follows a single-group model with no masking, focusing on treatment. It consists of a dose-escalation phase to determine the maximum tolerated dose and a dose-expansion phase to assess safety and efficacy further.
The study began on February 22, 2023, with an estimated completion date of July 7, 2025. The last update was submitted on July 7, 2025, indicating ongoing recruitment.
For investors, this study could impact Bristol-Myers Squibb’s stock performance, as successful results may enhance its position in the multiple myeloma market. The involvement of K36 Therapeutics and the innovative nature of KTX-1001 could also influence investor sentiment positively. Competitors in the oncology space should be monitored for similar advancements.
The study is ongoing, and further details are available on the ClinicalTrials portal.